Evidence map›Paper›PMID 34178496›Full record

ArticleCureus2021

Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma.

Shaunak K Pandya, Matthew Ulrickson, JiaXi Dong, Ryan Willen, Arati Pandya

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shaunak K PandyaInternal Medicine, Banner - University Medical Center Phoenix, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Matthew UlricksonHematology and Oncology, Stem Cell Transplant, Banner MD Anderson Cancer Center, Gilbert, USA.
JiaXi DongInternal Medicine, Banner - University Medical Center Phoenix, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Ryan WillenInternal Medicine, Banner - University Medical Center Phoenix, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Arati PandyaInternal Medicine, Banner - University Medical Center Phoenix, University of Arizona College of Medicine - Phoenix, Phoenix, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old male with metastatic renal cell carcinoma on pembrolizumab diagnosed with new-onset seronegative myasthenia gravis and review literature on its management.

Indexed as

autoimmunecheckpoint inhibitorsintravenous immunoglobulin (ivig)myasthenia gravispembrolizumabrenal cell carcinoma (rcc)seronegative

Identifiers

PMID34178496
PMCPMC8216640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.